# Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer

> **NCT01538537** · PHASE1 · COMPLETED · sponsor: **Traws Pharma, Inc.** · enrollment: 29 (actual)

## Conditions studied

- Advanced Cancer
- Solid Tumors
- Cancer
- Neoplasms

## Interventions

- **DRUG:** rigosertib sodium

## Key facts

- **NCT ID:** NCT01538537
- **Lead sponsor:** Traws Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2010-10
- **Final completion:** 2012-01
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2017-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01538537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01538537, "Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01538537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*